Park Therapeutics

Park Therapeutics is a private company that was formed to address the desperate need for better and safer analgesics. We recently acquired rights to PRK-101 which was discovered and originally developed by a pharma for strategic reasons. It is a PIII-ready NCE with a novel MOA that been extensively studied in a global development program of nearly 2,000 patients so has been significantly de-risked. It has already been shown to be effective in a wide range of indications and safer than existing alternatives, especially in terms of abuse and addiction potential. Park intends to develop PRK-101 for chronic lower back pain (cLBP), peripheral neuropathic pain and other chronic pain indications and plans to initiate PIII studies in 2021. We are currently seeking Series A funding, ex-US partnerships and additional clinical-stage pain programs to add to our pipeline.